Our staff will be delivering numerous presentations and abstracts at the upcoming 2014 American Society of Oncology (ASCO) Annual Meeting in Chicago, Ill. Mayo Medical Laboratories representatives will also be available at booth #2054 in the exhibit hall to discuss:
- SOLID TUMOR CANCERS: 50-gene next generation sequencing panel helps tailor therapies to the individual patient
- NON-SMALL CELL LUNG CARCINOMAS: Biomarker testing for targeted therapies
- BONE AND SOFT TISSUE TUMORS: Molecular genetic methods to support diagnostic confirmation and therapeutic considerations
- MELANOMA: FISH testing to aid in the differentiation of malignant from benign melanocytic lesions
- HEREDITARY COLON CANCER: Targeted testing and next generation sequencing
SOLID TUMOR CANCERS
This new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.
- A Test in Focus: Next Generation Sequencing Panel for Solid Tumor Cancers
- Test Catalog: Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing
- Press Release: Mayo Clinic Launches 50-Gene Cancer Panel Test
- Spanish Language Press Release: Mayo Clinic lanza panel de pruebas de 50 genes para cáncer
NON-SMALL CELL LUNG CARCINOMAS
Targeted inhibitors have proven to be remarkably successful against epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in patients with certain EGFR mutations and ALK rearrangements, and this has opened a new era of targeted therapy in advanced NSCLC.
- Communiqué: Biomarker Testing for Targeted Therapy in Non-Small Cell Lung Carcinomas
- Test Catalog: EGFRX / Lung Cancer, EGFR with ALK Reflex, Tumor
- Test Catalog: FLCA / Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue)
- Complete test information and appropriate test utilization: Utilization Spotlight
BONE AND SOFT TISSUE TUMORS
Traditionally, light microscopy has been considered the gold standard for the diagnosis of bone and soft tissue tumors. However, supportive molecular genetic methods are currently viewed as an important tool for diagnostic confirmation and therapeutic considerations in many bone and soft tissue tumors.
A (FISH)-based test panel has been developed as a diagnostic aid in the differentiation of malignant from benign melanocytic lesions. This test is intended to be used in conjunction with clinical and pathologic information to aid the pathologist in the differentiation of benign from malignant melanocytic lesions.
HEREDITARY COLON CANCER SYNDROMES
Our targeted test options and comprehensive next generation sequencing panel provide clinicians with a flexible and cost-effective approach to evaluating patients for hereditary colon cancer syndromes.
- Featured Topic: Hereditary Colon Cancer Syndromes – Next Generation Sequencing Panel
- Featured Topic: Hereditary Colon Cancer Syndromes – Comprehensive Testing
- Brochure: Hereditary Colon Cancer – Comprehensive Testing Options
MAYO CLINIC PRESENTATIONS
A complete list of Mayo Clinic presentations and abstracts can be found here.
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy
Session: Gastrointestinal (Colorectal) Cancer
Type: Poster Highlights Session
Date: Saturday, May 31, 2014
Time: 1:15 – 4:15 p.m.
Molecular subtyping of colon cancers and distinct prognostic groups
Session: Colorectal Cancer: Not Just One Disease
Type: Clinical Science Symposium
Date: Tuesday, June 03, 2014
Time: 9:45 – 11:15 a.m.